Zimmer Biomet Stock - analyst lens and weekly review
19.06.2026 - 17:04:14 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:01 CET. Details in the imprint.
Zimmer Biomet Holdings (US98956P1021) remains on the radar of healthcare investors even without a fresh company announcement this Friday. With no new filings or major news from the last 24 hours, the focus shifts to existing analyst views and how the stock has performed against key medical-technology peers in recent sessions.
Background and price data on Zimmer Biomet
All news, historical quotes and regulatory disclosures on Zimmer Biomet stock are bundled in the dedicated topic area and on the company’s investor-relations pages.
What the analysts say
Recent earnings and guidance for 2026 continue to frame the conversation around Zimmer Biomet. According to the company’s first-quarter 2026 release, management expects full-year revenue growth in the low- to mid-single-digit percent range, with an adjusted operating margin broadly stable compared with the prior year. The Q1 2026 IR materials outline that hip and knee implants remain the largest contributors to group sales.
Consensus data from major financial portals still shows a mixed but broadly constructive analyst backdrop. A majority of covering houses currently rate Zimmer Biomet between "Hold" and "Buy", with 12-month price targets clustering moderately above the recent share price, according to aggregated estimates from leading broker platforms. The dispersion of targets indicates neither extreme optimism nor deep pessimism in the sector context.
How it stacks up against peers
In the broader medical-technology universe, Zimmer Biomet often trades alongside large orthopedic and diversified device names such as Stryker, Johnson & Johnson’s MedTech division and Smith+Nephew. Sector trackers indicate that orthopedic-focused names have shown relatively stable performance over the past five trading days, with only modest percentage swings compared with more volatile biotech stocks.
Zimmer Biomet’s valuation metrics, including forward earnings and enterprise-value-to-EBITDA multiples, typically sit in a mid-range band within this peer group. Major data providers and broker overviews show that the stock trades at a discount to the fastest-growing robotics-exposed names, but roughly in line with other established implant manufacturers that face similar hospital budget dynamics and procedure-volume patterns.
How the company makes money
Zimmer Biomet generates most of its revenue from orthopedic implants and related surgical products used in joint reconstruction and trauma procedures. Core product families include knee and hip replacement systems, such as the Persona and Avenir lines, as well as sports medicine, extremities and spine solutions marketed to hospitals and surgeons worldwide.
Where the stock trades today
Zimmer Biomet Holdings stock (US98956P1021) trades on the New York Stock Exchange at around $120 per share as of 06/19/2026, 17:01 CET, reflecting the latest available consolidated quote data for the US listing.
Key facts on Zimmer Biomet stock
- Company: Zimmer Biomet Holdings, Inc.
- ISIN: US98956P1021
- WKN: A14M23
- Ticker: ZBH
- Venue: NYSE
- Price (as of 06/19/2026, 17:01 CET): 120.00 USD
- Market cap: 24,000,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care - Medical Devices
- Index membership: S&P 500
- Next earnings date: 08/05/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
